

EMA/665639/2022

European Medicines Agency decision P/0271/2022

of 10 August 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl) pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate (IPN60130), (EMA-003133-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0271/2022

of 10 August 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl) pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate (IPN60130), (EMA-003133-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Ipsen Pharma on 18 October 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 June 2022, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl) pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate (IPN60130), capsule, hard, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl) pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate (IPN60130), capsule, hard, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl) pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate (IPN60130), capsule, hard, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Ipsen Pharma, 65 Quai Georges Gorse 92100, 92100 - Boulogne-Billancourt, France.

EMA/PDCO/190959/2022
Amsterdam, 24 June 2022

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003133-PIP01-21

Scope of the application

Active substance(s):

(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl) pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate (IPN60130)

Condition(s):

Treatment of fibrodysplasia ossificans progressiva

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Ipsen Pharma

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Ipsen Pharma submitted for agreement to the European Medicines Agency on 18 October 2021 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 22 November 2021.

Supplementary information was provided by the applicant on 21 March 2022. The applicant proposed modifications to the paediatric investigation plan and to the waiver.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral of its own motion in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of fibrodysplasia ossificans progressiva

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- capsule, hard, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition:

Treatment of fibrodysplasia ossificans progressiva

2.1.1. Indication(s) targeted by the PIP

Treatment of fibrodysplasia ossificans progressiva

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Capsule, hard

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age-appropriate oral solid dosage form
Non-clinical studies	Not applicable
Clinical studies	Study 2 (D-CA-60130-452) Double-blind, randomised, placebo-controlled study with 36-month open-label extension to evaluate the efficacy and safety of oral IPN60130 in paediatric patients from 2 years of age to less than 18 years of age (and adults) with fibrodysplasia ossificans progressiva

Extrapolation, modelling and simulation studies	Study 3 (D-CA-60130-452 POP-PK and PK/PD modelling) Population pharmacokinetic (PK) modelling study to describe the PK profile of IPN60130 in children and adolescents from 2 years to under 18 years of age with fibrodysplasia ossificans progressiva
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes